Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection

F. Poordad, W. Sievert, Lindsay Mollison, M. Bennett, E. Tse, N. Bräu, J. Levin, T. Sepe, S.S. Lee, P. Angus, B. Conway, S. Pol, N. Boyer, J.P. Bronowicki, I. Jacobson, A.J. Muir, K.R. Reddy, E. Tam, G. Ortiz-Lasanta, V. De LédinghenM. Sulkowski, N. Boparai, F. Mcphee, E. Hughes, E.S. Swenson, P.D. Yin

    Research output: Contribution to journalArticle

    86 Citations (Scopus)

    Abstract

    Copyright 2015 American Medical Association. All rights reserved. IMPORTANCE: The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection. OBJECTIVE: To determine the rates of sustained virologic response (SVR) in patients receiving the 3-drug combination of daclatasvir (a pan-genotypic NS5A inhibitor), asunaprevir (an NS3 protease inhibitor), and beclabuvir (a nonnucleoside NS5B inhibitor). DESIGN, SETTING, AND PARTICIPANTS: This was an open-label, single-group, uncontrolled international study (UNITY-1) conducted at 66 sites in the United States, Canada, France, and Australia between December 2013 and August 2014. Patients without cirrhosis who were either treatment-naive (n = 312) or treatment-experienced (n = 103) and had chronic HCV genotype 1 infection were included. INTERVENTIONS: Patients received a twice-daily fixed-dose combination of daclatasvir, 30 mg; asunaprevir, 200 mg; and beclabuvir, 75 mg. MAIN OUTCOMES AND MEASURES: The primary study outcome was SVR12 (HCV-RNA
    Original languageEnglish
    Pages (from-to)1728-1735
    JournalJAMA - Journal of the American Medical Association
    Volume313
    Issue number17
    DOIs
    Publication statusPublished - 2015

    Fingerprint Dive into the research topics of 'Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection'. Together they form a unique fingerprint.

    Cite this